News

Under the agreement with the National Research Council of Canada (NRC), BioVeris has acquired worldwide, exclusive rights to commercialize products for possible use in the prevention, diagnosis and

The trial, which commenced on December 2, is currently being conducted at 32 centers across Canada and will evaluate ISA247, the company’s lead immunosuppressive compound, in patients with

The purchasing holding company is controlled by the Altor 2003 Fund and pre-existing shareholder Idosan. Novo Nordisk has been a minority shareholder, owning around 29% of the capital,

The vaccine is based on proprietary Antigen Express technology that employs modified peptide antigens to stimulate immunity. Antigen Express proprietary technologies dramatically enhance the immunogenicity of small fragments

The special protocol assessment (SPA) specifies the trial objectives and design, clinical endpoints, and planned analyses that would be needed to apply for product approval. The phase III,

The legal actions are the result of a seven-month investigation during which the two companies collaborated to track down the illegal drug distributors operating these websites as well

The Transdur-based transdermal sufentanil product is intended to provide extended chronic pain relief for up to seven days, as compared to the three days of relief provided with

The results show that Nuvigil (armodafinil), a single-isomer of the active pharmaceutical ingredient contained in Cephalon’s Provigil (modafinil), significantly improves wakefulness and the overall clinical condition of patients

The ruling was made following a three-day hearing by a board of appeal of the European Patent Office (EPO). Lilly ICOS stated that the decision confirmed the patent’s